Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $276

Ligand Pharmaceuticals Incorporated -0.35% Pre

Ligand Pharmaceuticals Incorporated

LGND

204.92

204.92

-0.35%

0.00% Pre
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ: LGND) with a Buy and raises the price target from $270 to $276.